Clinical trials
Transplantation clinical trials
Below are recruiting transplantation clinical trials, each written for real people, not researchers. We’re tracking 1,452 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06490627RecruitingPhase 2
thalidomide for transfusion-dependent beta thalassemia
This trial tests different doses of thalidomide to see if it can reduce or eliminate the need for blood transfusions in people with beta thalassemia major or intermedia.
Karachi, SindhAges 8–35 - NCT07015242RecruitingPhase 2
Liso-cel as first treatment for primary CNS lymphoma
This study tests an investigational cell therapy called liso-cel for people with primary central nervous system lymphoma who cannot have a stem cell transplant and have already responded to initial chemotherapy. The goal is to see if liso-cel can help control the disease better and possibly improve outcomes.
Aurora, ColoradoAges 18 years+ - NCT07016438Recruiting
Study of PAL-222 for stubborn skin ulcers
This trial tests a new treatment, PAL-222, for skin ulcers that haven't improved much after 4 weeks of standard care. It aims to see if PAL-222 can help these wounds heal better.
Kyoto, Shogoin-kawahara-cho, Sakyo-ku, KyotoAges 20 years+ - NCT07015723Enrolling by invitation
Liver fat study in living donors
This study looks at stored medical data from living liver donors to better understand fat in the liver (steatosis). It may help improve future transplant care.
Rotterdam, South HollandAges 18–60 - NCT07017946RecruitingPhase 1/Phase 2
Gut bacteria transplant for fast-progressing ALS
This trial tests whether a transplant of healthy gut bacteria (called a microbiome transplant) can slow down ALS in people whose disease is progressing rapidly. It aims to see if changing the gut environment can help with symptoms and quality of life.
Durham, North CarolinaAges 18 years+ - NCT07017608Recruiting
Breathing effort before and after tube removal
This study measures how hard your breathing muscles work while you are on a ventilator and right after the breathing tube is removed. It may help doctors understand how to make the transition easier.
Toronto, OntarioAges 18 years+ - NCT07015684RecruitingPhase 1
Radioactive antibody and transplant for advanced sickle cell disease
This trial tests a radioactive antibody (131I-apamistamab) as part of conditioning before a stem cell transplant from a matched sibling donor. It aims to make the transplant safer and more effective for people with severe sickle cell disease.
New York, New YorkAges 12–50 - NCT07012044RecruitingPhase 1
Cedazuridine and decitabine after stem cell transplant for childhood leukemia
This trial tests if adding two chemotherapy drugs (cedazuridine and decitabine) along with a growth factor (filgrastim) can help prevent leukemia from coming back after a stem cell transplant. It is for children and young adults with high-risk acute myeloid leukemia who are in remission after transplant.
Birmingham, AlabamaAges Up to 21 years - NCT07003737Recruiting
Blinatumomab before stem cell transplant for high-risk B-ALL
This trial tests giving a drug called blinatumomab before a stem cell transplant for people with high-risk B-cell acute lymphoblastic leukemia (B-ALL) that is in remission and has no detectable cancer cells. The goal is to see if this extra treatment helps prevent the leukemia from coming back after transplant.
Hangzhou, ZhejiangAges 18–65 - NCT07009548Enrolling by invitationPhase 4
CytoGam for CMV in solid organ transplant recipients
This trial tests whether adding CytoGam (an antibody treatment) to standard antiviral therapy can better treat CMV (a common virus) in people who have received a solid organ transplant. It may help those with high virus levels or a new infection after transplant.
Pittsburgh, PennsylvaniaAges 18–75 - NCT07006532Recruiting
Tocilizumab for chronic active antibody-mediated rejection
This trial tests whether the drug tocilizumab can help treat chronic active antibody-mediated rejection after a kidney transplant. It is for people whose kidney function is still fairly good and who have certain findings on biopsy.
TehranAges 18 years+ - NCT07006506RecruitingPhase 2
Belumosudil to prevent graft-versus-host disease after transplant
This study tests whether a drug called belumosudil can help prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for people who have had a recent transplant and are at risk for GVHD.
Basking Ridge, New JerseyAges 18 years+ - NCT07006272Recruiting
Closed-loop pump vs islet transplant for unstable type 1 diabetes
This study compares two advanced treatments for type 1 diabetes that is hard to control: a closed-loop insulin pump system (which automatically adjusts insulin) versus islet cell transplantation (which replaces the cells that make insulin). It is for people whose blood sugar stays very unstable despite using the best current therapies.
Lyon, Auvergne-Rhône-AlpesAges 18 years+ - NCT07011238Recruiting
Memory B cells and anti-HLA antibodies in kidney transplant patients
This study looks at how memory B cells (a type of immune cell) relate to antibodies against HLA in people waiting for a kidney transplant. It aims to better understand immune responses, which could help improve transplant matching and outcomes.
RouenAges 18 years+ - NCT07002099RecruitingPhase 2
Selinexor, methotrexate, and rituximab with radiation for new CNS lymphoma
This trial tests a combination of three drugs (selinexor, high-dose methotrexate, and rituximab) plus radiation for people with newly diagnosed central nervous system (CNS) lymphoma who cannot have a stem cell transplant. The goal is to see if this treatment can help control the cancer.
SuzhouAges 18 years+ - NCT06998706RecruitingPhase 1
Testing patient's own lung stem cells for ILD
This study tests whether a patient's own lung stem cells can be used to repair damaged lungs in people with interstitial lung disease. It is an early-stage trial to see if the treatment is safe and may help improve breathing.
Qionghai, HainanAges 40–75 - NCT07001540RecruitingPhase 2
Targeted drug combo for relapsed DLBCL
This trial tests a combination of targeted antibody drugs (polatuzumab vedotin and rituximab) plus two chemo drugs (gemcitabine and oxaliplatin) for people with DLBCL whose cancer returned after their first treatment and who cannot have a stem cell transplant. The goal is to see if this combination works better as a second-line treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05198570Recruiting
Measuring how acyclovir moves in children with cancer
This study checks how acyclovir behaves in the body when it’s given by mouth or through an IV to children receiving cancer care. It may help doctors better choose doses and monitor the medicine in kids who need prevention or treatment of certain viral infections.
Trieste, TSAges 6 months–18 years - NCT06987214RecruitingPhase 1
Regenerative stem cell therapy for bronchiectasis
This trial tests whether transplanting your own lung stem cells can repair damaged airways caused by bronchiectasis. It is for people with moderate to severe breathing impairment and aims to improve lung function.
Qionghai, HainanAges 25–80 - NCT06976229RecruitingPhase 1
Stem cell therapy for recent spinal cord injury
This phase 1 trial tests a new treatment made from stem cells (XS228) for people who had a spinal cord injury 14 to 60 days ago. Doctors want to see if it's safe and if it might help with recovery.
Guangzhou, GuangdongAges 18–65 - NCT04257747Recruiting
3T MRI study of hand and forearm blood flow
This study uses a powerful MRI scanner (3 Tesla) to measure blood flow in the arteries of the hand and forearm under normal and certain medical conditions. You may qualify if you’re an adult and can safely have an MRI, either as a healthy volunteer or someone needing specific hand/arm surgery.
AmiensAges 18 years+ - NCT06946953RecruitingPhase 1/Phase 2
Stem cell transplant for COPD: a safety and early efficacy study
This trial tests whether transplanting a patient's own lung stem cells can improve lung function in people with chronic obstructive pulmonary disease (COPD). It aims to see if this treatment is safe and helps repair damaged lung tissue.
Qionghai, HainanAges 40–80 - NCT06946654Recruiting
Health Check for Older Adults Before Stem Cell Transplant
This study looks at whether a special health evaluation designed for older adults can help doctors better plan stem cell transplants for people 55 and older with blood disorders. You would receive a series of questionnaires and tests to assess your overall health before transplant.
BeijingAges 55 years+ - NCT06932562RecruitingPhase 3
Testing linvoseltamab vs standard care for myeloma patients not eligible for transplant
This trial compares a new drug called linvoseltamab to standard treatments for multiple myeloma. It is for people who cannot have a stem cell transplant and have not had extensive prior therapy.
AdelaideAges 18 years+
Hear when a new Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for transplantation?
- Yes. Clin2 currently lists 1,452 recruiting transplantation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a transplantation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a transplantation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.